Results 211 to 220 of about 336,282 (259)

Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis. [PDF]

Nature
Cho S, Rhee S, Madl CM, Caudal A, Thomas D, Kim H, Kojic A, Shin HS, Mahajan A, Jahng JW, Wang X, Thai PN, Paik DT, Wang M, Mullen M, Baker NM, Leitz J, Mukherjee S, Winn VD, Woo YJ, Blau HM, Wu JC.   +21 more
europepmc   +1 more source

METTL3 Silencing Suppresses Cardiac Fibrosis Post Myocardial Infarction via m6A Modification of SMOC2. [PDF]

J Cell Mol Med
He Y, Pan X, Liu Z, Zuo P, Sheng Z, Hao C, Tao Z, Chen Z, Song J, Ma G, Ling S.   +10 more
europepmc   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Dressed in Collagen: 2D and 3D Cardiac Fibrosis Models. [PDF]

Int J Mol Sci
Cardona-Timoner M, Gomes RN, Nascimento DS.   +2 more
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease. [PDF]

J Arrhythm
William J, Muthana H, Hogarty J, Taylor A, Hare JL, Mariani J, Patel H, Wong G, Stub D, Kaye DM, Prabhu S, Kistler PM, Voskoboinik A.   +12 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Apoptosis-Related Non-Coding RNAs in Cardiac Fibrosis and Heart Failure: Implications for Pathogenesis and Therapy. [PDF]

J Inflamm Res
Wu H, Xia L, Liu C.
europepmc   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Administration of a novel reprogramming formula improves cardiac function and decreases cardiac fibrosis in a myocardial infarction model. [PDF]

JTCVS Open
Mathison M, Pathan SS, Lackan A, Yang J, Mohamed TMA, Rosengart TK.   +5 more
europepmc   +1 more source